# US 2020/0138927 A1 · Non-cross-linked acellular pertussis antigens for use in combination vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0138927 A1
- Document ID: US20200138927A1
- Status: Published application
- Kind: A1
- Application number: 16/696,328
- Filed: 2019-11-26
- Published: 2020-05-07
- Earliest claimed: 2012-10-12
- Assignees: Glaxosmithkline Biologicals SA
- Applicants: GlaxoSmithKline Biologicals SA
- Inventors: Lorenzo TARLI; Mario CONTORNI; Alessandro BARTALESI
- Web page: https://patentgrep.com/patent/US20200138927A1

## CPC

- A61K 39/0018: {Combination vaccines based on acellular diphtheria-tetanus-pertussis}
- A61K 39/0016: {Combination vaccines based on diphtheria-tetanus-pertussis}
- A61K 39/099: {Bordetella}
- A61K 39/13: Poliovirus
- A61K 39/292: {Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2730/10134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/30034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to stable compositions comprising acellular pertussis antigens that have not been cross-linked with a cross-linking agent such as formaldehyde or glutaraldehyde and their use as acellular pertussis components in combination vaccines. Processes for preparing these antigens and compositions are also disclosed.

## Claims

### Claim 1

A process for preparing an aP component, comprising:
a. growing a culture of a B. pertussis strain expressing a genetically detoxified pertussis toxin;
b. purifying two or more B. pertussis antigens from the culture to obtain two or more batches each containing a different purified B. pertussis antigen; and
c. mixing the two or more batches to prepare the aP component,
wherein the process is characterised in that the purified B. pertussis antigens are not treated with a cross-linking agent, and
wherein the aP component comprises at least two non-cross-linked B. pertussis antigens selected from PT, FHA and pertactin with the proviso that any PT is genetically detoxified.

### Claim 2 (depends on 1)

The process of claim 1, wherein the genetically detoxified pertussis toxin is PT-9K/129G.
